Chimeric antigen receptor (CAR) T cell therapy has recently approved for CD-19-positive B-cell malignancies, such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma in Japan. CAR-T therapy may develop cytokine release syndoromes as well as central nervous system complications (CRES/ICANS), including encephalopathy, consciousness distrubence, apahsia, seizure, motor weakness, and cerebral edema. Although the pathomechanism of CRES/ICANS remains unsolved, an appropriate intervention is important for patients. In addition, several chemotherapeutic agenets used before CAR-T cell therapy may also lead to the development of central nervous system disorders. Therefore, neurologists must be familiar with the complications of newly developed chemotherapies.

Download full-text PDF

Source
http://dx.doi.org/10.11477/mf.1416201711DOI Listing

Publication Analysis

Top Keywords

car-t cell
8
cell therapy
8
central nervous
8
nervous system
8
[neurotoxicities associated
4
associated car-t
4
cell therapy]
4
therapy] chimeric
4
chimeric antigen
4
antigen receptor
4

Similar Publications

Chimeric antigen receptor (CAR) T-cell products axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel) are approved for relapsed/refractory large B-cell lymphoma (R/R LBCL). Emerging evidence indicates that delayed CAR T-cell infusion, including prolonged time from leukapheresis to infusion, known as vein-to-vein time (V2Vt), may adversely impact clinical outcomes. We conducted a systematic literature review (SLR) and meta-analysis to identify differences in V2Vt in patients with R/R LBCL treated with axi-cel, tisa-cel, or liso-cel.

View Article and Find Full Text PDF

Purpose: We designed a CD19-targeted chimeric antigen receptor (CAR) comprising a calibrated signaling module, termed 1XX, that differs from that of conventional CD28/CD3ζ and 4-1BB/CD3ζ CARs. Preclinical data demonstrated that 1XX CARs generated potent effector function without undermining T-cell persistence. We hypothesized that 1XX CAR T cells may be effective at low doses and elicit minimal toxicities.

View Article and Find Full Text PDF

Background/purpose: Immunotherapies, such as CAR-T, have revolutionized cancer treatment for some cancers. However, these treatments often require active participation of a family member or friend to act as a caregiver at home for several weeks after infusion. Given the novelty of CAR-T, there is a need to better understand the experience of patients receiving these treatments and their caregivers.

View Article and Find Full Text PDF

Cell therapy is an emerging strategy for precision treatment of scleroderma. This review systematically summarizes the research progress of mesenchymal stem cell (MSC) and chimeric antigen receptor T cell (CAR-T) therapies in scleroderma and discusses the challenges and future directions for development. MSCs possess multiple functions, including immunomodulation, anti-fibrosis, and promotion of vascular regeneration, all of which can improve multiple pathological processes associated with scleroderma.

View Article and Find Full Text PDF

Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context.

Front Immunol

January 2025

Unité Mixte de Recherche (UMR) 7365 Centre National de la Recherche Scientifique (CNRS), Ingénierie Moléculaire, Cellulaire et Physiopathologie (IMoPA), Université de Lorraine, Nancy, France.

CAR-T cell therapy has revolutionized immunotherapy but its allogeneic application, using various strategies, faces significant challenges including graft-versus-host disease and graft rejection. Recent advances using Virus Specific T cells to generate CAR-VST have demonstrated potential for enhanced persistence and antitumor efficacy, positioning CAR-VSTs as a promising alternative to conventional CAR-T cells in an allogeneic setting. This review provides a comprehensive overview of CAR-VST development, emphasizing strategies to mitigate immunogenicity, such as using a specialized TCR, and approaches to improve therapeutic persistence against host immune responses.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!